Gene: PAX2

5076
FSGS7|PAPRS
paired box 2
protein-coding
10q24.31
Ensembl:ENSG00000075891 MIM:167409 Vega:OTTHUMG00000018913 UniprotKB:Q02962
NG_008680.2
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.720e-2 (AD)  2.235e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LTK0.637
C1QL20.614
SDK10.574
TP53I110.574
GJB30.567
PRTN30.551
GPR830.544
ZNF4690.541
OR10G90.537
FAM163A0.534

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
C21orf91-0.402
FAM107B-0.398
ASPA-0.393
COL4A5-0.392
DOCK5-0.392
TMEM144-0.391
FOLH1-0.389
ST18-0.388
TMEM235-0.388
C10orf90-0.381

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA"27188386
D001280AtrazineAtrazine results in decreased expression of PAX2 mRNA25929836
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of PAX2 mRNA26377693
C022921benzo(k)fluoranthenebenzo(k)fluoranthene results in decreased expression of PAX2 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PAX2 mRNA21803694
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of PAX2 mRNA25566086
C006780bisphenol Abisphenol A affects the methylation of PAX2 promoter27334623
C006780bisphenol Abisphenol A results in decreased expression of PAX2 mRNA25181051
D002104CadmiumCadmium results in decreased expression of PAX2 mRNA21120746
D002104CadmiumCadmium results in increased expression of PAX2 mRNA24376830
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PAX2 gene20938992
C470995corexit 9500[Petroleum co-treated with corexit 9500] affects the expression of PAX2 mRNA24496467
D004051Diethylhexyl PhthalateDiethylhexyl Phthalate results in decreased expression of PAX2 mRNA22677342
C118739entinostatentinostat results in increased expression of PAX2 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA"27188386
C024565ethylene dichlorideethylene dichloride results in decreased expression of PAX2 mRNA28189721
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PAX2 gene20938992
C069837fullerene C60fullerene C60 results in increased expression of PAX2 mRNA19167457
D007854LeadLead affects the expression of PAX2 mRNA28903495
D008070LipopolysaccharidesPAX2 protein results in increased susceptibility to Lipopolysaccharides21131441
D018021Lithium ChlorideLithium Chloride results in increased expression of PAX2 mRNA17506889
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PAX2 gene20938992
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of PAX2 mRNA"20188158
D037742Nanotubes, Carbon"Nanotubes, Carbon affects the expression of PAX2 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of PAX2 mRNA"25620056
C028007nickel monoxidenickel monoxide results in increased expression of PAX2 mRNA19167457
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX2 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of PAX2 mRNA26272509
D010578Petroleum[Petroleum co-treated with corexit 9500] affects the expression of PAX2 mRNA24496467
D012969Sodium FluorideSodium Fluoride results in increased expression of PAX2 mRNA27862939
D014284TriiodothyronineTriiodothyronine results in increased expression of PAX2 mRNA17403546
D013629TamoxifenTamoxifen results in decreased expression of PAX2 mRNA25123088
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of PAX2 mRNA21296121
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PAX2 mRNA21570461|2405805
D013853ThioacetamideThioacetamide results in increased expression of PAX2 mRNA23411599
D014241TrichloroethyleneTrichloroethylene results in decreased expression of PAX2 mRNA25549359
C012589trichostatin Atrichostatin A results in increased expression of PAX2 mRNA24935251
C012589trichostatin Atrichostatin A results in decreased expression of PAX2 mRNA15901671
D014635Valproic AcidValproic Acid affects the expression of PAX2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased methylation of PAX2 gene29154799
D014635Valproic AcidValproic Acid results in decreased expression of PAX2 mRNA15901671
D019287Zinc SulfateZinc Sulfate results in decreased expression of PAX2 mRNA17506889

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0000987proximal promoter sequence-specific DNA binding-IDA19118900  
GO:0003677DNA binding-IDA24676634  
GO:0003677DNA binding-ISS-  
GO:0005515protein binding-IPI9178767  15785774  21575608  
GO:0008134transcription factor binding-IPI24676634  
GO:0016175superoxide-generating NADPH oxidase activity-ISS-  
GO:0044212transcription regulatory region DNA binding-IDA9178767  16368682  16735463  19048125  
GO ID GO Term Qualifier Evidence PubMed
GO:0001655urogenital system development-ISS-  
GO:0001658branching involved in ureteric bud morphogenesis-IEP1337742  
GO:0001658branching involved in ureteric bud morphogenesis-ISS-  
GO:0001709cell fate determination-ISS-  
GO:0001823mesonephros development-ISS-  
GO:0001843neural tube closure-ISS-  
GO:0002072optic cup morphogenesis involved in camera-type eye development-ISS-  
GO:0003337mesenchymal to epithelial transition involved in metanephros morphogenesis-ISS-  
GO:0003406retinal pigment epithelium development-ISS-  
GO:0006351transcription, DNA-templated-ISS-  
GO:0006366transcription by RNA polymerase II-TAS8760285  
GO:0007409axonogenesis-TAS9106533  
GO:0007501mesodermal cell fate specification-ISS-  
GO:0007568aging-IEA-  
GO:0007601visual perception-TAS9106533  
GO:0010001glial cell differentiation-ISS-  
GO:0021554optic nerve development-ISS-  
GO:0021631optic nerve morphogenesis-ISS-  
GO:0021633optic nerve structural organization-ISS-  
GO:0021650vestibulocochlear nerve formation-ISS-  
GO:0031667response to nutrient levels-IEA-  
GO:0035566regulation of metanephros size-IMP17513325  
GO:0035799ureter maturation-ISS-  
GO:0039003pronephric field specification-ISS-  
GO:0042472inner ear morphogenesis-ISS-  
GO:0043010camera-type eye development-ISS-  
GO:0043066negative regulation of apoptotic process-IDA10980123  
GO:0043066negative regulation of apoptotic process-IMP17357786  
GO:0043069negative regulation of programmed cell death-ISS-  
GO:0043154negative regulation of cysteine-type endopeptidase activity involved in apoptotic process-IDA10980123  17357786  
GO:0043491protein kinase B signaling-ISS-  
GO:0045892negative regulation of transcription, DNA-templated-IMP19118900  
GO:0045893positive regulation of transcription, DNA-templated-IDA16368682  17357786  19048125  24676634  
GO:0045918negative regulation of cytolysis-IMP19118900  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA16735463  
GO:0045944positive regulation of transcription by RNA polymerase II-ISS-  
GO:0048793pronephros development-ISS-  
GO:0048854brain morphogenesis-ISS-  
GO:0048863stem cell differentiation-ISS-  
GO:0050679positive regulation of epithelial cell proliferation-IDA17357786  
GO:0055114oxidation-reduction process-IEA-  
GO:0060231mesenchymal to epithelial transition-ISS-  
GO:0061360optic chiasma development-ISS-  
GO:0070301cellular response to hydrogen peroxide-ISS-  
GO:0071300cellular response to retinoic acid-ISS-  
GO:0071333cellular response to glucose stimulus-ISS-  
GO:0071364cellular response to epidermal growth factor stimulus-IEA-  
GO:0072075metanephric mesenchyme development-ISS-  
GO:0072108positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis-ISS-  
GO:0072162metanephric mesenchymal cell differentiation-ISS-  
GO:0072179nephric duct formation-ISS-  
GO:0072189ureter development-ISS-  
GO:0072205metanephric collecting duct development-ISS-  
GO:0072207metanephric epithelium development-IEP7856737  
GO:0072221metanephric distal convoluted tubule development-ISS-  
GO:0072289metanephric nephron tubule formation-ISS-  
GO:0072300positive regulation of metanephric glomerulus development-ISS-  
GO:0072305negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis-ISS-  
GO:0072307regulation of metanephric nephron tubule epithelial cell differentiation-ISS-  
GO:0072593reactive oxygen species metabolic process-ISS-  
GO:0090102cochlea development-ISS-  
GO:0090103cochlea morphogenesis-ISS-  
GO:0090190positive regulation of branching involved in ureteric bud morphogenesis-ISS-  
GO:1900212negative regulation of mesenchymal cell apoptotic process involved in metanephros development-ISS-  
GO:1900215negative regulation of apoptotic process involved in metanephric collecting duct development-ISS-  
GO:1900218negative regulation of apoptotic process involved in metanephric nephron tubule development-ISS-  
GO:2000378negative regulation of reactive oxygen species metabolic process-IDA17357786  
GO:2000594positive regulation of metanephric DCT cell differentiation-ISS-  
GO:2000597positive regulation of optic nerve formation-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA19048125  
GO:0005730nucleolus-IDA-  
GO:0005764lysosome-IEA-  
GO:0005794Golgi apparatus-IDA-  
GO:0005815microtubule organizing center-IDA18000879  
GO:0032991protein-containing complex-ISS-  
GO:0032993protein-DNA complex-ISS-  
GO:0034451centriolar satellite-IDA18000879  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29459480Occupational exposure to pesticides is associated with differential DNA methylation. (2018 Jun)van der Plaat DAOccup Environ Med